NICE News

Updates to managing COVID-19 guideline

We have added recommendations on:

• molnupiravir and remdesivir for people with COVID-19 who do not need supplemental oxygen

• awake prone positioning.

• non-invasive respiratory support.

Neonatal parenteral nutrition quality standard

We’ve published a new quality standard on neonatal parenteral nutrition (intravenous feeding). It covers babies born preterm, up to 28 days after their due birth date, and babies born at term, up to 28 days after their birth. The quality standard advises neonatal parenteral nutrition is delivered through infusion sets, syringes and standardised bags that are protected from light. It also says that healthcare professionals should have access to a specialist nutritional multidisciplinary team.
 
This quality standard builds on our existing guideline on neonatal parenteral nutrition.

Elosulfase alfa recommended for rare life-limiting metabolic disorder

We have published draft guidance recommending elosulfase alfa for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Our positive recommendation follows the collection of real-world data from 69 people who received NHS-funded treatment as part of a managed access agreement. This enabled new evidence to be presented showing some long-term benefits of elosulfase alfa slowing the progression of MPS 4A.

Have your say on our quality standard on indoor air quality

Help shape our quality standard on indoor air quality at home. It covers residential buildings including nursing homes, care homes and children’s homes.
 
The draft standard sets out that healthcare professionals should ask people with respiratory conditions or cardiovascular conditions who have repeated or worsening respiratory symptoms about their housing conditions.
 
Consultation is open until Monday 11 April.

Comment on a consultation

Our current consultations include:

• Indoor air quality at home
  Submit your comments by Monday 11 April 2022.
• GID-MT563 NPi-200 for pupillary light reflex in critical care patients
  Submit your comments by Monday 11 April 2022.
• Nivolumab with platinum and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
  Submit your comments by Wednesday 13 April 2022.
• Diabetes (type 1 and type 2) in children and young people: diagnosis and management - medicines for type 2 diabetes (update)
  Submit your comments by Thursday 14 April 2022.

Join a committee

We have a number of vacancies for health, public health and lay people to join our committees. Topics include maternal and child nutrition, antenatal care and alcohol-use disorders. Join us and have an active role in producing a guideline or quality standard.

Observe a meeting

We’re currently holding all our public meetings virtually. You'll need to register in advance to join. 

Upcoming public meeting:

• Friday 22 April 2022 – Medical technology advisory committee
  Registration closes Wednesday 13 April 2022.
  Agenda and register

Methods research priorities: continuing the journey

Join our virtual event to learn more about:

• our methods research priorities
• our ongoing research, undertaken in collaboration with partners in the UK and across Europe
• how our research is supporting the delivery of our 5-year strategy.

Thursday 31 March, 11am to 12:15pm.

Methods research helps NICE to keep improving the methods we use to produce guidance. It also helps us anticipate and adapt to innovative new health technologies and treatments, policy developments and changes in health and social care delivery. We're actively involved in this type of research and currently working on 10 priority research topics.

Building an evidence standards framework for artificial intelligence-enabled digital health technologies

In this Lancet article, we outline our work to develop an evidence standards framework for artificial intelligence-enabled digital health technologies. The framework is a set of universal standards describing the evidence requirements of different types of digital health technologies. It:

• makes it easier for innovators and commissioners to understand what good levels of evidence for digital health technologies look like
• helps commissioners make more informed and consistent decisions when purchasing digital health technologies
• helps innovators understand how to demonstrate the effectiveness and value of their product when submitting their technology for NICE evaluation or selling directly to the NHS.

Changes to our privacy notice

We’ve made some changes to our privacy notice. Through regular newsletters and ad-hoc email communications, we’ll continue to send you the latest news, updates and information from NICE.
 
For more information about how we process your personal data, please see our privacy notice.